Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $349.6 million.

  • C4 Therapeutics' Liabilities and Shareholders Equity fell 29.40% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 19.64%. This contributed to the annual value of $349.6 million for FY2024, which is 7.13% down from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Liabilities and Shareholders Equity is $349.6 million, which was down 7.13% from $376.5 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Liabilities and Shareholders Equity registered a high of $506.8 million during FY2021, and its lowest value of $349.6 million during FY2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $385.6 million, with a median of $376.5 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 238.35% in 2020, then fell by 14.98% in 2022.
  • Over the past 5 years, C4 Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $400.1 million in 2020, then increased by 26.65% to $506.8 million in 2021, then dropped by 14.98% to $430.8 million in 2022, then declined by 12.62% to $376.5 million in 2023, then decreased by 7.13% to $349.6 million in 2024.